Jin-A Chae

Title: Innovations by Jin-A Chae in Cancer Therapy

Introduction

Jin-A Chae is an accomplished inventor based in Seoul, South Korea. She has made significant contributions to the field of cancer therapy through her innovative inventions. With a total of two patents, her work focuses on improving adoptive cell therapies and adenovirus production.

Latest Patents

Jin-A Chae's latest patents include "Anti-Sialyl Tn chimeric antigen receptors" and "Adenovirus producing novel cell line and the use thereof." The first invention provides improved compositions for adoptive cell therapies targeting cancers that express the glycoepitope STn on TAG-72. The second invention relates to a cell line designed to produce adenoviruses with a reduced likelihood of generating replication-competent adenoviruses (RCA). This innovation allows for better regulation of virus production during gene therapy, minimizing tissue damage and toxic effects associated with adenovirus overproduction. Additionally, her cell line demonstrates superior adenovirus production capabilities compared to conventional cell lines like HEK 293.

Career Highlights

Throughout her career, Jin-A Chae has worked with notable companies such as Helixmith Co., Ltd and Viromed Co., Ltd. Her experience in these organizations has contributed to her expertise in the field of biotechnology and cancer treatment.

Collaborations

Jin-A Chae has collaborated with esteemed colleagues, including Seung Shin Yu and Richard Morgan. These partnerships have further enhanced her research and development efforts in innovative therapies.

Conclusion

Jin-A Chae's contributions to cancer therapy through her patents and collaborations highlight her role as a leading inventor in the field. Her work continues to pave the way for advancements in medical treatments and therapies.